Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

PROK - ProKidney Corp. Stock Price, Fair Value and News

$2.29-0.04 (-1.72%)
Delayed as of 20 Aug 2025, 03:02 pm ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PROK Price Action

Last 7 days

4.9%

Last 30 days

-25.4%

Last 90 days

205.2%

Trailing 12 Months

-2.1%

PROK Stock Price

PROK RSI Chart

NovDec2025FebMarAprMayJunJulAug020406080100

PROK Valuation

Market Cap

682.0M

Price/Earnings (Trailing)

-9.41

Price/Sales (Trailing)

33.05

EV/EBITDA

-3.79

Price/Free Cashflow

-4.65

PROK Price/Sales (Trailing)

2023202420250100200300400500600700

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PROK Fundamentals

PROK Revenue

Rev. Growth (Yr)

-9.24%

Rev. Growth (Qtr)

-14.12%

2021202220232024202505M10M15M20M

PROK Earnings

Earnings (TTM)

-72.5M

Earnings Growth (Yr)

-32.35%

Earnings Growth (Qtr)

1.09%

20212022202320242025-140M-120M-100M-80M-60M-40M-20M

PROK Profitability

EBT Margin

-828.54%

Return on Equity

7.23%

Return on Assets

-19.48%

Free Cashflow Yield

-21.49%

PROK Investor Care

Shares Dilution (1Y)

26.33%

Diluted EPS (TTM)

-0.59

Revenue Breakdown

As of: Mar 31, 2025
202220232024202501M2M3M4M5M6M
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
202120222023202405M10M15M20M
Net sales
YearQ1Q2Q3Q4
20250000
202421.6M21.0M20.4M19.8M
202311.6M17.2M21.2M22.1M
2022004.8M6.0M
202101.2M2.4M3.6M
202000043.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
 CEO
 WEBSITEprokidney.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES87

ProKidney Corp. Frequently Asked Questions

What is the ticker symbol for ProKidney Corp.? What does PROK stand for in stocks?

PROK is the stock ticker symbol of ProKidney Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProKidney Corp. (PROK)?

As of Tue Aug 19 2025, market cap of ProKidney Corp. is 682 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PROK stock?

You can check PROK's fair value in chart for subscribers.

Is ProKidney Corp. a good stock to buy?

The fair value guage provides a quick view whether PROK is over valued or under valued. Whether ProKidney Corp. is cheap or expensive depends on the assumptions which impact ProKidney Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PROK.

What is ProKidney Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Aug 19 2025, PROK's PE ratio (Price to Earnings) is -9.41 and Price to Sales (PS) ratio is 33.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PROK PE ratio will change depending on the future growth rate expectations of investors.